Metraipolis › archive › dc_f0fc0631646e

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting… — Europe PMC PMID:40973846

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40973846
DOI
10.1007/s00277-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-09T20:38:54.656Z
SHA-256 of the archived text
5c23748cb6fc3a83809ed67a16170c80a692c0994208fc3031f1c452e9d60ec9
Stable URL of this page
https://metraipolis.com/documento/dc_f0fc0631646e

How to cite

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting… — Europe PMC PMID:40973846 — Europe PMC (en), https://europepmc.org/article/MED/40973846 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f0fc0631646e (Metraipolis archive dc_f0fc0631646e, sha256 5c23748cb6fc3a83809ed67a16170c80a692c0994208fc3031f1c452e9d60ec9)
BibTeX
@misc{dcf0fc0631646e,
  title = {Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting… — Europe PMC PMID:40973846},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40973846},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f0fc0631646e; sha256 5c23748cb6fc3a83809ed67a16170c80a692c0994208fc3031f1c452e9d60ec9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40973846. Agents can read the archived copy with the MCP tool read_document.